Geron Co.

Geron achieved 17% year-over-year net revenue growth for RYTELO and 24% net revenue growth in H1 2026 while cutting total operating expenses by 4%, driven by a refocused commercial push into high-volume community treatment centers. Management reiterated 2026 RYTELO revenue guidance at the mid-to-high end of $220–240 million, maintained total operating expense guidance of $230–240 million, and holds $327 million in cash to fund commercial investment. The company is evaluating an IMpactMF interim analysis event-threshold change with regulators, plans a gated European commercialization strategy, and expects final overall survival results in relapsed/refractory myelofibrosis in H2 2028. » Plus sur finance.yahoo.com

Geron reported revenue of $57.48 million in the second quarter of 2026, 4.1% above analysts' estimates, driven by higher RYTELO sales. Adjusted loss per share was $0.02, missing expectations by $0.01, while operating expenses in the first half fell 4%. Management expects to finish the year at the mid-to-upper end of its revenue guidance ($220–240 million) and sees continued commercial momentum despite ongoing losses. » Plus sur de.investing.com

Effective June 17, 2026, Geron granted stock options to purchase 690,000 shares to eight newly hired employees as inducements for employment. The options carry an exercise price of $1.23 (closing price on grant date), a ten-year term and vest over four years, with 12.5% vesting at six months and the remainder vesting in equal installments over the following 42 months, subject to continued employment. » Plus sur finance.yahoo.com